Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - Unauthorized drugs seized from Tokyo Beauty in Burnaby, B.C., may pose serious health risks


OTTAWA, ON, July 7, 2021 /CNW/ -

Summary

Issue

Health Canada has seized several health products?including an acne gel, an antibiotic cream, eye drops and eyewashes?from Tokyo Beauty in the Metropolis at Metrotown mall, Burnaby, B.C., because they are unauthorized drugs and may pose serious health risks.

According to the product labels, the products contain prescription drugs (see table below for details). Prescription drugs should only be taken under the advice and supervision of a health care professional because of the risk of interactions with other medications and side effects. Prescription drugs can only be legally sold with a prescription.

Selling unauthorized drugs is illegal in Canada. Unauthorized drugs have not been approved by Health Canada, which means that they have not been assessed for safety, effectiveness and quality and may pose serious health risks. They may contain ingredients, additives or contaminated ingredients not listed on the label. In addition, they may lack the active ingredients Canadians would expect them to contain to help maintain and improve their health. For all of these reasons, unauthorized health products could cause serious health effects.

All of the unauthorized health products that Health Canada seized are packaged and labelled in Japanese characters. As a result, information about ingredients, usage, dosage and side effects may not be understood by all consumers.

Health Canada has previously seized unauthorized products from another Tokyo Beauty store with the same owner, located in Richmond, B.C., and issued advisories in March 2021 and February 2019. The Department will continue to take action to stop this illegal activity and update Canadians as needed.

Affected products

Photo

Product

Risk


Dalacin T Gel 1%

Antibacterial gel for acne

Labelled (in Japanese) to contain clindamycin

 


Gentashin 0.1% Antibiotic Cream

Antibiotic cream

Labelled (in Japanese) to contain gentamicin


Kobayashi Aibon/Eyebon Eyewash (blue)

Eyewash

Labelled (in Japanese) to contain aminocaproic acid


Kobayashi Aibon/Eyebon Eyewash Medicala (black)

Eyewash

Labelled (in Japanese) to contain aminocaproic acid


Santen Sante Beautéye Contact

Eye drops

Labelled (in Japanese) to contain neostigmine methylsulfate


Santen Sante FX Neo (blue) 

Eye drops

Labelled (in Japanese) to contain neostigmine methylsulfate and aminocaproic acid

 


Santen Sante FX Neo (silver)

Eye drops

Labelled (in English) to contain neostigmine methylsulfate and aminocaproic acid


Santen Sante PC

Eye drops

Labelled (in Japanese) to contain neostigmine methylsulfate

What you should do

Background

Aminocaproic acid: This is a prescription drug ingredient used to decrease bleeding in various clinical situations. Exposure to aminocaproic acid in the eye may affect the eye itself, and the acid may be absorbed through the tear ducts into the blood. Side effects may include watery eyes, vision changes, headache, dizziness, nausea, muscle weakness and skin rash.

Clindamycin: In topical format (i.e., applied to the skin), this is a prescription antibiotic approved in Canada to treat bacterial infections, including those associated with acne. The product should not be used in individuals with a history of ulcerative colitis (inflamed bowel) or a history of inflamed bowel associated with antibiotic use (antibiotic-associated colitis). Side effects may include dry or scaly skin, peeling skin, a stinging or burning feeling on the skin, eye pain, itching, hives, redness and gastrointestinal symptoms (such as indigestion and gas). Safety and effectiveness in children under the age of 12 has not been established.

Gentamicin is a prescription antibiotic drug applied topically (to the skin) to treat minor skin infections. It can cause skin redness and irritation. Prolonged use can cause fungal or bacterial infections. Gentamicin may be absorbed into the blood if applied to large areas of skin, especially if the areas are cracked or raw, which increases the risk of serious side effects. Serious side effects include allergic reactions (e.g., rash, hives, and red, swollen, blistered, or peeling skin with or without fever, trouble breathing, swelling of the mouth, face, lips, tongue or throat) and kidney and hearing damage. It should not be used in patients who are allergic to gentamicin. Gentamicin may interact with other drugs and should be used with caution with other antibiotics, anti-cancer drugs, diuretics, immunosuppressants, and nonsteroidal anti-inflammatories.

Neostigmine methylsulfate: There are no approved eye drops containing neostigmine methylsulfate on the Canadian market. In the past, drugs similar to neostigmine were used to treat glaucoma. These medications are no longer widely used because of the significant number of potential eye-related side effects, including blurred distance vision, frontal headaches, twitching lids, red eyes, cataracts, allergic reactions, iris cysts, retinal detachment and the potential for causing a specific type of glaucoma attack. In addition, absorption into the nose via the tear duct may cause serious cardiac and respiratory side effects.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...



News published on and distributed by: